<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949191</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54828-801</org_study_id>
    <nct_id>NCT04949191</nct_id>
  </id_info>
  <brief_title>The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.</brief_title>
  <official_title>An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have&#xD;
      participated in a previous parent study to treat advanced malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2 Open-Label, Multicenter, Rollover Study to evaluate the long term safety and&#xD;
      tolerability of Pemigatinib and to provide Continued Treatment for Participants With Advanced&#xD;
      Malignancies Previously Enrolled in Studies of Pemigatinib&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2021</start_date>
  <completion_date type="Anticipated">October 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>up to 30 days after last dose</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>Study Treatment 1: Pemigatinib (INCB054828)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemigatinib will be taken orally once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 2: Pemigatininb+ Retifanlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and retifanlimab will be administered once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Treatment 3: Pemigatininb + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants rolling over from study INCB 54828-101 only will receive pemigatinib once daily and pembroluzimab as per dosage instructions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemigatinib</intervention_name>
    <description>Pemigatinib tablets taken by mouth once daily as per protocol</description>
    <arm_group_label>Study Treatment 1: Pemigatinib (INCB054828)</arm_group_label>
    <arm_group_label>Study Treatment 2: Pemigatininb+ Retifanlimab</arm_group_label>
    <arm_group_label>Study Treatment 3: Pemigatininb + Pembrolizumab</arm_group_label>
    <other_name>INCB054828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Retifanlimab</intervention_name>
    <description>Retifanlimab is administered over 60 minutes once every 4 weeks (Day 1 of a 28-day cycle)</description>
    <arm_group_label>Study Treatment 2: Pemigatininb+ Retifanlimab</arm_group_label>
    <other_name>INCMGA0012</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Commercially labeled products</description>
    <arm_group_label>Study Treatment 3: Pemigatininb + Pembrolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled and receiving treatment in an Incyte-sponsored clinical study&#xD;
             (parent protocol) of pemigatinib as monotherapy or combination therapy.&#xD;
&#xD;
          -  Currently benefiting from and tolerating treatment with pemigatinib, as determined by&#xD;
             the investigator.&#xD;
&#xD;
          -  Demonstrated compliance, as assessed by the investigator, with the parent protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, and any&#xD;
             other study procedures.&#xD;
&#xD;
          -  Currently have no evidence of progressive disease, as determined by the investigator,&#xD;
             following treatment with pemigatinib as monotherapy or combination therapy.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Able to access pemigatinib commercially or outside of a clinical trial.&#xD;
&#xD;
          -  Permanently discontinued from the parent protocol for any reason.&#xD;
&#xD;
          -  No longer meet the inclusion/exclusion criteria from the parent protocol if still&#xD;
             receiving treatment.&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding or participants expecting to conceive or&#xD;
             father children within the projected duration of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Langmuir</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oncology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemigatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

